New Drug Info – Ampydin
AnonymousFebruary 20, 2007 at 8:33 am
[B]Orphan Drug 4-Aminopyridine (Ampydin) for Chronic Motor and Sensory Deficits of GBS[/B]
On December 20, the FDA granted orphan drug status for an immediate release, orally administered version of 4-aminopyridine (Ampydin, made by Neurorecovery, Inc) in the treatment of chronic functional motor and sensory deficits resulting from Guillain-Barré syndrome (GBS).
According to a company news release, 4-aminopyridine is currently on the FDA’s compounding for compassionate use list for treatment of certain neuropathies and for spinal cord injury and multiple sclerosis.
An international phase 3 trial of the product for the GBS indication is expected to begin in the United States, Canada, and the European Union during the first half of 2007.
Related Article => [HTML]http://www.pslgroup.com/dg/20777A.htm[/HTML]
AnonymousFebruary 20, 2007 at 7:11 pm
Did a Google, found this:
[QUOTE]What’s new in the world of Research
updated 17 February, 2006
This page will contain information on global research into issues of interest to GBS/CIDP patients and their healthcare providers. Older information will be replaced as new information becomes available, so please check often![/QUOTE]
[COLOR=”Red”]Assessment of Chronic Guillain-Barre Syndrome Improvement with Use of 4-aminopyridine [registration required] [/COLOR]
[COLOR=”RoyalBlue”]This US study will assess the usefulness and safety of 4-amino-pyridine (4-AP) in patients suffering chronic functional deficits from GBS. 4-AP is a potassium channel blocker that could potentially improve nerve conduction, particularly across partially demyelinated axons. Increasing nerve conduction may improve motor performance as well as decreased fatigue. Over 20% of GBS patients have permanent residual motor deficits that affect their daily life.
NLM Identifier NCT00056810
posted here: 05.2003[/COLOR]
You must be logged in to reply to this topic.